Antibe Therapeutics’ Game Changing Pain Relief Drug

© 2020 All Rights Reserved.

Antibe is rather unique in the Canadian marketplace for having two best-in-class divisions:
  • A biotech division where we’re developing a family of potentially game-changing drugs.
  • And a commercial business with $10 Mil of revenue and this business is in regenerative medicine.
A diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine. Its blockbuster drug platform has a lead asset in Phase 2. And the combined pipeline is targeting a global market opportunity in excess of $20 billion. The commercial division in regenerative medicine is on a global growth trajectory in the dental biologics market. Pursuing Blockbuster Drug Opportunities in Pain & Inflammation: Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin. Building a Commercial Force in Regenerative Medicine: Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products for oral and maxillofacial surgery. Since its inception in 1997, Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. More recently, Citagenix initiated a strategic growth initiative in the United States, the largest global market for oral regenerative medicine. For more information on Antibe Therapeutics Inc. (ATE.V) please fill out the form below.

Request Investor Info